ANIP - ANI Pharmaceuticals, Inc.
NEXT EARNINGS:
Feb 27, 2026
(in 2 days)
EPS Est: $2.01
Price:
--
--
|
CONSENSUS:
Buy
DETAILS
|
PRICE TARGET:
$111.67
DETAILS
HIGH:
$124.00
LOW:
$90.00
MEDIAN:
$121.00
CONSENSUS:
$111.67
UPSIDE:
45.59%
Market Cap:
1.72B
Volume:
284,667
Avg Volume:
443,581
52 Week Range:
54.1-99.5
Sector:
Healthcare
Industry:
Drug Manufacturers - Specialty & Generic
Beta:
0.50
Last Dividend:
$N/A
Exchange:
NASDAQ
Country:
US
Employees:
897
IPO Date:
2000-05-05
EPS (TTM):
-1.04
P/E Ratio:
-57.66
Revenue (TTM):
614.38M
Total Assets:
1.28B
Total Debt:
624.09M
Cash & Equiv:
144.86M
Rev Growth (5Y):
24.3%
EPS Growth (5Y):
N/A
FCF Growth (5Y):
21.1%
ROCE:
-0.4%
Debt/Equity:
1.46
Earnings History
| Date | EPS Actual | EPS Est | EPS Surprise | Rev Actual | Rev Est | Rev Surprise |
|---|---|---|---|---|---|---|
| 2025-11-07 | $2.04 | $1.74 | +17.2% | $227.8M | $232.2M | -1.9% |
| 2025-08-08 | $1.80 | $1.38 | +30.4% | $211.4M | $208.8M | +1.2% |
| 2025-05-09 | $1.70 | $1.37 | +24.1% | $197.1M | $188.7M | +4.4% |
| 2025-02-28 | $1.63 | $1.41 | +15.6% | $190.6M | $170.0M | +12.1% |
| 2024-11-08 | $1.34 | $1.09 | +22.9% | $148.3M | $175.1M | -15.3% |
| 2024-08-06 | $1.02 | $0.93 | +9.7% | $138.0M | $129.1M | +7.0% |
| 2024-05-10 | $1.21 | $0.98 | +23.5% | $137.4M | $125.5M | +9.5% |
| 2024-02-29 | $1.00 | $0.80 | +25.0% | $131.7M | $122.2M | +7.7% |
| Metric | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 614.38M | 486.82M | 316.38M | 216.14M | 208.47M | 206.55M | 201.58M | 176.84M | 128.62M | 76.32M | 55.97M | 30.08M |
| Net Income | (18.52M) | 18.78M | (47.90M) | (42.60M) | (22.55M) | 6.09M | 15.49M | (1.08M) | 3.93M | 15.38M | 28.75M | 301,000 |
| EPS | -1.04 | 0.95 | -3.05 | -3.40 | -1.88 | 0.51 | 1.33 | -0.09 | 0.34 | 1.34 | 2.61 | -0.92 |
| Total Assets | 1.28B | 904.42M | 760.09M | 771.60M | 461.19M | 456.79M | 430.60M | 412.14M | 322.86M | 285.26M | 263.71M | 44.50M |
| Total Debt | 624.09M | 285.67M | 286.52M | 287.37M | 185.69M | 185.75M | 183.01M | 201.51M | 120.64M | 113.43M | 110.69M | 0 |
| Cash & Equivalents | 144.86M | 221.12M | 48.23M | 100.30M | 7.86M | 62.33M | 43.01M | 31.14M | 27.36M | 154.68M | 169.04M | 11.11M |
| Operating Cash Flow | 64.02M | 118.96M | (31.20M) | 3.32M | 15.27M | 45.63M | 67.07M | 39.42M | 27.47M | 17.26M | 22.03M | (5.48M) |
| Free Cash Flow | 47.06M | 100.45M | (47.66M) | (20.32M) | (53.05M) | 18.08M | 56.16M | (68.57M) | (121.59M) | (15.42M) | (13.72M) | (5.67M) |
| FCF per Share | 2.44 | 5.58 | -2.93 | -1.61 | -4.43 | 1.53 | 4.81 | -5.94 | -10.62 | -1.36 | -1.25 | -1.12 |
| Book Value | 428.53M | 457.60M | 338.54M | 358.74M | 195.70M | 212.79M | 197.26M | 174.76M | 169.65M | 160.08M | 139.78M | 40.96M |
| Cash & ST Investments | 151.17M | 221.12M | 48.23M | 100.30M | 7.86M | 62.33M | 43.01M | 31.14M | 27.36M | 154.68M | 169.04M | 11.11M |
| ROC Equity | -0.04 | 0.04 | -0.14 | -0.12 | -0.12 | 0.03 | 0.08 | -0.01 | 0.02 | 0.10 | 0.21 | 0.01 |